Design Therapeutics, Inc. (DSGN) Tops Q2 EPS by 2c

Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q2 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.

You May Also Be Interested In

• Goldman Sachs Reiterates Buy Rating on Targa Resources (TRGP) ahead of earnings
• Citi Reiterates Buy Rating on Estee Lauder (EL), Adding Upside 90-Day Catalyst Watch
• Karooooo Ltd. (KARO) PT Raised to $70 at Needham